



Marco Valgimigli

Kontakt

Marco Valgimigli

Publikationen (5)

Iglesias J, Windecker S, Valgimigli M, Heg D, Kaiser C, Weilenmann D, Kurz D, Roffi M, Losdat S, Muller O, Pilgrim T. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. *Int J Cardiol* 2021; 334:37-41.

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Brinkert M, Muller O, Tüller D, Degrauwé S, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. *Cardiovasc Revasc Med* 2021; 34:3-10.

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Rigamonti F, Lanz J, Tüller D, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. *J Am Heart Assoc* 2019; 8:e013607.

Iglesias J, Windecker S, Jüni P, Zwahlen M, Odutayo A, Valgimigli M, Eeckhout E, Losdat S, Stortecky S, Tapponnier M, Kaiser C, Weilenmann D, Moarof I, Kurz D, Roffi M, Heg D, Muller O, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. *Lancet* 2019; 394:1243-1253.

Iglesias J, Windecker S, Jüni P, Eeckhout E, Valgimigli M, Heg D, Tapponnier M, Kaiser C, Weilenmann D, Vuilliomenet A, Kurz D, Roffi M, Zaugg S, Muller O, Pilgrim T. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. *EuroIntervention* 2018; 14:692-699.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch